277.64
price down icon2.58%   -7.34
after-market Handel nachbörslich: 277.64
loading

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

pulisher
Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 17, 2025
pulisher
Jun 16, 2025

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others - insights.citeline.com

Jun 16, 2025
pulisher
Jun 15, 2025

(MDGL) Investment Analysis - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 13, 2025

Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Predicts MDGL FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Jun 06, 2025
pulisher
Jun 03, 2025

(MDGL) On The My Stocks Page - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 02, 2025

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewswire

Jun 02, 2025
pulisher
May 29, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc. - Defense World

May 29, 2025
pulisher
May 28, 2025

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com

May 28, 2025
pulisher
May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com

May 26, 2025
pulisher
May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK

May 26, 2025
pulisher
May 25, 2025

Cetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World

May 25, 2025
pulisher
May 23, 2025

When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com

May 23, 2025
pulisher
May 17, 2025

In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha

May 17, 2025
pulisher
May 16, 2025

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma - insights.citeline.com

May 16, 2025
pulisher
May 15, 2025

Will Other Major MASH Deals Follow GSK/Boston Pharma? - insights.citeline.com

May 15, 2025
pulisher
May 13, 2025

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - AOL.com

May 13, 2025
pulisher
May 13, 2025

Transcript : Madrigal Pharmaceuticals, Inc.Special Call - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Where are the Opportunities in (MDGL) - news.stocktradersdaily.com

May 13, 2025
pulisher
May 13, 2025

Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN

May 13, 2025
pulisher
May 11, 2025

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN

May 11, 2025
pulisher
May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus

May 11, 2025
pulisher
May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus

May 11, 2025
pulisher
May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times

May 10, 2025
pulisher
May 10, 2025

Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com

May 10, 2025
pulisher
May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.

May 10, 2025
pulisher
May 08, 2025

Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey

May 08, 2025
pulisher
May 07, 2025

Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey

May 07, 2025
pulisher
May 06, 2025

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey

May 06, 2025
pulisher
May 05, 2025

What is B. Riley’s Estimate for MDGL FY2028 Earnings? - Defense World

May 05, 2025
pulisher
May 04, 2025

Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st

May 04, 2025
pulisher
May 03, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 03, 2025

Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus

May 03, 2025
pulisher
May 02, 2025

(MDGL) Trading Signals - news.stocktradersdaily.com

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus

May 02, 2025
pulisher
May 02, 2025

UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus

May 02, 2025
pulisher
May 02, 2025

UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN

May 02, 2025
pulisher
May 02, 2025

UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives Increased Price Target from Analyst | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals Inc (MDGL) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance

May 02, 2025
$20.52
price down icon 1.06%
$35.91
price down icon 0.64%
$21.27
price up icon 1.67%
$104.85
price down icon 0.99%
$104.80
price down icon 0.28%
biotechnology ONC
$267.12
price up icon 0.12%
Kapitalisierung:     |  Volumen (24h):